孟鲁司特对载脂蛋白E/低密度脂蛋白受体双敲除小鼠动脉粥样硬化形成的影响。
The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
作者信息
Jawien J, Gajda M, Wołkow P, Zurańska J, Olszanecki R, Korbut R
机构信息
Jagiellonian University School of Medicine, Cracow, Poland.
出版信息
J Physiol Pharmacol. 2008 Sep;59(3):633-9.
We have shown that inhibitors of five lipoxygenase activating protein (FLAP)--MK-886 and BAYx1005 inhibit atherosclerosis in apolipoprotein E/LDL receptor-double knockout mice. We, therefore, investigated whether cysteinyl leukotrienes receptor inhibitor--montelukast, given at a dose of 0.125 microg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR-DKO mouse model montelukast significantly decreased atherogenesis, measured both by "en face" method (25.5+/-2.% vs. 17.23 +/- 1.8%) and "cross-section" method (455,494 +/- 26,477 microm(2) vs. 299,201 +/- 20,373 microm(2)). The results were, however, less pronounced, comparing to FLAP inhibitors. This is the first report showing the effect of montelukast on atherogenesis in gene-targeted mice.
我们已经表明，5-脂氧合酶激活蛋白（FLAP）抑制剂——MK-886和BAYx1005可抑制载脂蛋白E/低密度脂蛋白受体双敲除小鼠的动脉粥样硬化。因此，我们研究了半胱氨酰白三烯受体抑制剂——孟鲁司特，在16周内每天以每100毫克体重0.125微克的剂量给药，是否也能减轻动脉粥样硬化的发生。在载脂蛋白E/低密度脂蛋白受体双敲除（apoE/LDLR-DKO）小鼠模型中，孟鲁司特显著降低了动脉粥样硬化的发生，通过“正面”方法（25.5±2.%对17.23±1.8%）和“横截面”方法（455,494±26,477平方微米对299,201±20,373平方微米）测量均是如此。然而，与FLAP抑制剂相比，结果不太明显。这是第一份显示孟鲁司特对基因靶向小鼠动脉粥样硬化发生影响的报告。
Zotero 插件